EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs Treprostinil (Primary) ; Treprostinil (Primary) ; Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms EXPEDITE
- Sponsors United Pharmaceuticals
- 22 Apr 2019 Planned End Date changed from 1 Oct 2019 to 1 Jun 2020.
- 22 Apr 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Jan 2020.
- 01 Oct 2018 Status changed from not yet recruiting to recruiting.